Artivion (NYSE:AORT) Trading Down 5.5% – Here’s What Happened

Shares of Artivion, Inc. (NYSE:AORT) were down 5.5% during mid-day trading on Tuesday . The stock traded as low as $35.35 and last traded at $35.3210. 266,449 shares were traded during mid-day trading, a decline of 32% from the average daily volume of 389,271 shares. The stock had previously closed at $37.39.

Trending Headlines about Artivion

Here are the key news stories impacting Artivion this week:

• Positive Sentiment: Q4 results topped expectations — revenue grew ~19% year‑over‑year and EPS beat consensus, supporting revenue momentum and margin recovery; this helps justify the current rally. Earnings & Company Page
• Positive Sentiment: Short interest fell ~15.4% in February to ~1.39M shares (~3.2% of float); lower short exposure reduces one source of downside selling and can make up‑moves easier to sustain. Short Interest/Insider Page
• Positive Sentiment: Institutional investors have increased or initiated positions in recent quarters (multiple funds cited), indicating professional conviction that could support longer‑term demand. Institutional Holdings
• Neutral Sentiment: Analyst coverage is mixed — consensus is a “Moderate Buy” with an average target near $49, but some shops have trimmed targets or moved to Hold, reflecting divergent views on near‑term upside. Analyst Notes
• Negative Sentiment: Large, broad insider selling across Feb. 23–24 (CEO James P. Mackin, EVP Lance Berry, SVPs and CAO made sizable open‑market disposals). While filings suggest open‑market liquidity/scheduled sales rather than insider panic, the scale and breadth can create short‑term selling pressure and investor unease. SEC filings: CEO Form 4 and related officer filings. CEO Form 4 EVP Form 4

Wall Street Analysts Forecast Growth

AORT has been the topic of a number of recent research reports. Wall Street Zen lowered Artivion from a “buy” rating to a “hold” rating in a report on Saturday, February 14th. Canaccord Genuity Group lowered their price objective on shares of Artivion from $51.00 to $48.00 and set a “buy” rating on the stock in a research report on Friday, February 13th. Needham & Company LLC restated a “buy” rating and set a $58.00 price objective on shares of Artivion in a research report on Monday, February 2nd. Citizens Jmp increased their price target on shares of Artivion from $47.00 to $53.00 and gave the stock a “market outperform” rating in a report on Friday, November 7th. Finally, Oppenheimer restated an “outperform” rating and issued a $50.00 price objective on shares of Artivion in a research report on Friday, November 7th. Six investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat.com, Artivion presently has an average rating of “Moderate Buy” and a consensus price target of $48.97.

Artivion Price Performance

The stock’s fifty day moving average price is $42.09 and its 200-day moving average price is $43.05. The company has a debt-to-equity ratio of 0.49, a quick ratio of 2.62 and a current ratio of 3.53. The firm has a market cap of $1.83 billion, a PE ratio of 56.79 and a beta of 1.59.

Artivion (NYSE:AORT) last released its quarterly earnings data on Thursday, February 12th. The company reported $0.17 EPS for the quarter, topping analysts’ consensus estimates of $0.14 by $0.03. Artivion had a net margin of 2.21% and a return on equity of 7.43%. The firm had revenue of $118.30 million for the quarter, compared to the consensus estimate of $116.42 million. The business’s quarterly revenue was up 19.2% on a year-over-year basis. As a group, equities analysts forecast that Artivion, Inc. will post 0.37 EPS for the current fiscal year.

Insider Activity

In related news, insider John E. Davis sold 3,773 shares of the business’s stock in a transaction dated Monday, February 23rd. The shares were sold at an average price of $37.59, for a total value of $141,827.07. Following the sale, the insider directly owned 190,943 shares in the company, valued at $7,177,547.37. The trade was a 1.94% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Lance A. Berry sold 4,981 shares of the stock in a transaction dated Monday, February 23rd. The shares were sold at an average price of $37.59, for a total transaction of $187,235.79. Following the completion of the sale, the executive vice president directly owned 148,450 shares in the company, valued at approximately $5,580,235.50. The trade was a 3.25% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 104,010 shares of company stock valued at $4,197,721 in the last 90 days. Insiders own 7.60% of the company’s stock.

Institutional Trading of Artivion

Large investors have recently made changes to their positions in the stock. Vanguard Group Inc. raised its stake in Artivion by 4.7% in the 4th quarter. Vanguard Group Inc. now owns 3,170,089 shares of the company’s stock valued at $144,588,000 after purchasing an additional 141,030 shares during the last quarter. Morgan Stanley grew its holdings in shares of Artivion by 0.8% during the fourth quarter. Morgan Stanley now owns 2,256,742 shares of the company’s stock worth $102,930,000 after buying an additional 18,248 shares in the last quarter. State Street Corp raised its position in shares of Artivion by 2.9% in the fourth quarter. State Street Corp now owns 1,584,920 shares of the company’s stock valued at $72,288,000 after buying an additional 44,641 shares during the last quarter. Fred Alger Management LLC raised its position in shares of Artivion by 4.2% in the fourth quarter. Fred Alger Management LLC now owns 1,372,572 shares of the company’s stock valued at $62,603,000 after buying an additional 55,322 shares during the last quarter. Finally, Invesco Ltd. lifted its stake in shares of Artivion by 211.9% during the fourth quarter. Invesco Ltd. now owns 1,101,239 shares of the company’s stock valued at $50,228,000 after buying an additional 748,119 shares during the period. Institutional investors and hedge funds own 86.37% of the company’s stock.

About Artivion

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.